Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis

Allanore, Y; Meune, C; Vonk, M C; et al; Distler, O; Walker, U A

Abstract: OBJECTIVES: To measure the prevalence of, and factors associated with, left ventricular (LV) dysfunction in systemic sclerosis (SSc). METHODS: The EUSTAR database was first searched. A case-control study of a patient subset was then performed to further identify independent factors associated with LV dysfunction by simple and multiple regression. RESULTS: Of 7073 patients, 383 (5.4%) had an LV ejection fraction (EF) of <55%. By multiple regression analysis, age, sex, diffuse cutaneous disease, disease duration, digital ulcerations, renal and muscle involvement, disease activity score, pulmonary fibrosis and pulmonary arterial hypertension were associated with LV dysfunction. In the second phase, 129 patients with SSc with LVEF <55% were compared with 256 patients with SSc with normal LVEF. Male sex (OR 3.48; 95% CI 1.74 to 6.98), age (OR 1.03; 95% CI 1.01 to 1.06), digital ulcerations (OR 1.91; 95% CI 1.05 to 3.50), myositis (OR 2.88; 95% CI 1.15 to 7.19) and use of calcium channel blockers (OR 0.41; 95% CI 0.22 to 0.74) were independent factors associated with LV dysfunction. CONCLUSION: The prevalence of LV dysfunction in SSc is 5.4%. Age, male gender, digital ulcerations, myositis and lung involvement are independently associated with an increased prevalence of LV dysfunction. Conversely, the use of calcium channel blockers may be protective.

DOI: https://doi.org/10.1136/ard.2008.103382

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-43810

Originally published at:
DOI: https://doi.org/10.1136/ard.2008.103382
Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients

Allanore Y (1), Meune C (2), Vonk MC (3), Airo P (4), Hachulla E (5), Caramaschi P (6), Riemekasten G (7), Cozzi F(8), Beretta L (9), Derk CT (10), Komócsi A (11), Farge D (12), Balbir A (13), Ricceri V (14), Distler O (15), Chialà A (16), Del Papa N (17), Simic Pasalic K (18), Ghio M (19), Stamenkovic B (20), Rednic S (21), Host N (22), Pellerito R (23), Zegers E (24), Kahan A (1), Walker UA (25), Matucci-Cerinic M (26) and EUSTAR coauthors*

From:
1Université Paris Descartes; APHP; Hôpital Cochin, Service de Rhumatologie A, Paris, France
2Université Paris Descartes ; APHP ; Hôpital Cochin, Service de Cardiologie, Paris, France
3Reumatology, Radboud University Nijmegen Medical Centre, huispost 470, PB 91016500 HB Nijmegen, Netherlands
4Servizio di Reumatologia ed Immunologia Clinica, Spedali Civili, Brescia, Italia
5Service de Médecine Interne, Lille, France
6Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Policlinico G.B. Rossi, P.le Scuro, 37134 Verona, Italy
7Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie der Charité Universitätsmedizin, Centrum 12, Charité Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
8Rheumatology Unit, University of Padova, Via Giustiniani 2-35128 Padova, Italy.
9IRCCS Fondazione Policlinico-Mangiagalli-Regina Elena and University of Milan, Milan, Italy
10Division of Rheumatology, Thomas Jefferson University, 613 Curtis Bldg, 1015 Walnut Street, Philadelphia, PA 19107, USA
11Heart Institute, Faculty of Medicine, University of Pécs, 13. Ifjuság Str., H-7623 Pécs Hungary
12Service de médecine interne et pathologie vasculaire, hôpital Saint-Louis, INSERM U697, 1 avenue Claude-Vellefaux, 75010 Paris, France
13B. Shine Department of Rheumatology, Rambam Health Care Campus, Haifa, Israel.
14Cattedra di Reumatologia, Department of Clinical and Medical Therapy, University of Rome La Sapienza, Viale del Policlinico 155, Rome, Italy
15University Hospital Zurich, Zurich, Switzerland
16DIMIMP, Sezione di Reumatologia, Università degli Studi di Bari, Italia.
17Department of Rheumatology, G. Pini Hospital, Milano, Italy
18Institute Rheumatology, Belgrade, Serbia
19Department of Internal Medicine, University and San Martino Hospital of Genoa, Genoa
20Department of Rheumatology, Institute for Prevention and Treatment of Rheumatic and Cardiovascular Disease Niška Banja, Medical Faculty, University of Niš, Niš, Serbia
21Department of Rheumatology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Str. Cliniciilor 2-4, 400006 Cluj-Napoca, Romania
22Department of Cardiology Y, Bispebjerg University Hospital, DK-2400 Copenhagen, Denmark
23Ospedale Mauriziano Umberto I, Largo Turati 62, 10128 Torino, Italy
24Cardiology, Radboud University Nijmegen Medical Centre, huispost 470, PB 91016500 HB Nijmegen, Netherlands
25Medizinische Universitätsklinik Freiburg, Switzerland.
26Department of BioMedicine, Division of Rheumatology AOUC, University of Florence, Italy

*Eustar co-authors are listed in the supplemental file 2
**Abbreviated title:** left ventricular dysfunction in systemic sclerosis

**Corresponding author:**
Pr Yannick Allanore, MD, PhD
Service de Rhumatologie A, Hôpital Cochin
Université Paris Descartes
27 rue du Faubourg Saint-Jacques
75014 Paris, France
e-mail: yannick.allanore@cch.aphp.fr

"The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article to be published in Annals of the Rheumatic Diseases editions and any other BMJPG products to exploit all subsidiary rights, as set out in our licence http://ard.bmjjournals.com/ifora/licence.pdf "

**Word count:** Abstract 194 words; manuscript 1500 words

**Key words** Systemic sclerosis; ventricular dysfunction; heart failure; predictor analysis; calcium channel blocker
Abstract

Study objectives and methods To measure the prevalence of, and factors associated with, left ventricular (LV) dysfunction in SSc, we first queried the EUSTAR database. In a second phase, we performed a case-control study of a patient subset, to further identify independent factors associated with LV dysfunction by simple and multiple regression.

Results Among 7,073 patients, 383 (5.4%) had a LV ejection fraction (EF) <55%. By multiple regression analysis, age, sex, diffuse cutaneous disease, disease duration, digital ulcerations, renal and muscle involvement, disease activity score, pulmonary fibrosis and pulmonary arterial hypertension (PAH) were associated with LV dysfunction. In a second phase, 129 SSc patients with LVEF <55% were compared with 256 SSc patients with normal LVEF. Male sex (OR 3.48; 95% CI 1.74-6.98), age (OR 1.03; 95% CI 1.01-1.06), digital ulcerations (OR 1.91; 95% CI 1.05-3.50), myositis (OR 2.88; 95% CI 1.15-7.19), and calcium channel blockers (CCB) use (OR 0.41; 95% CI 0.22-0.74) were independent factors associated with LV dysfunction.

Conclusion The prevalence of LV dysfunction in SSc is 5.4%. Age, male gender, digital ulcerations, myositis and lung involvement are independently associated with increased prevalence of LV dysfunction. Conversely, CCB use may appear as protective.
Introduction

The prevalence of primary myocardial involvement by systemic sclerosis (SSc) has been subject to particular attention in recent years (1-3). It appears that once clinically apparent, cardiac involvement has a very poor prognosis (4-7). While the overall long-term prognosis of patients with SSc seems to have improved in recent years, the proportion of deaths due to heart disease has not changed significantly (7). The objective of this study was to precisely measure the prevalence of LV dysfunction ascertained by standard echocardiography, and to identify factors associated with a depressed LV ejection fraction (EF).

Patient population and methods

We first queried the EUSTAR database that has been described previously in details (8). LVEF was measured echocardiographically at each participating center, using Simpson's method: LVEF was classified as depressed if <55% or <50%. In a second phase, we performed a case-control study of a patient subset, to further identify independent factors associated with LV dysfunction by simple and multiple regression including parameters not registered in the EUSTAR database. Methods and statistical analysis details are available in supplemental file 1.

Results

By April 2008, 7,283 patients had been enrolled. Since neither LVEF nor the presence of LV dysfunction was recorded in 209, this analysis includes data collected in 7,073 patients (mean age 56±14 years, 981 [13.9%] men). A total of 383 patients had a reduced LVEF corresponding to a 5.4% prevalence. The main characteristics of patients with versus those without LV dysfunction are shown in table 1.
Table 1: Characteristics of patients presenting with SSc and depressed versus normal left ventricular ejection fraction

<table>
<thead>
<tr>
<th></th>
<th>Left ventricular ejection fraction</th>
<th></th>
<th></th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Depressed (n=383)</td>
<td>Normal (n=6,690)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y (means ± SD)</td>
<td>61.3±13.4</td>
<td>56.1±13.7</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Men/women (%)</td>
<td>23/77</td>
<td>13/87</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Disease duration, y</td>
<td>12.0±9.7</td>
<td>9.6±7.8</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cutaneous subtype;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse (%)</td>
<td>47.5</td>
<td>32.0</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Friction rub (%)</td>
<td>19.2</td>
<td>10.8</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Synovitis (%)</td>
<td>23.3</td>
<td>16.2</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Raynaud’s syndrome (%)</td>
<td>96.9</td>
<td>95.4</td>
<td></td>
<td>0.181</td>
</tr>
<tr>
<td>Digital ulceration (%)</td>
<td>52.4</td>
<td>30.5</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Muscle weakness (%)</td>
<td>47.9</td>
<td>25.9</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pulmonary fibrosis (plain X-ray) (%)</td>
<td>56.9</td>
<td>35.5</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Elevated systolic pulmonary artery pressure (%)</td>
<td>50.7</td>
<td>18.7</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Palpitation (%)</td>
<td>48.9</td>
<td>23.1</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Conduction abnormality on electrocardiogram (%)</td>
<td>33.3</td>
<td>9.1</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Renal crisis (%)</td>
<td>8.2</td>
<td>1.9</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Positive anti-nuclear antibodies (%)</td>
<td>92.4</td>
<td>91.9</td>
<td>0.736</td>
<td></td>
</tr>
<tr>
<td>Positive anti-topoisomerase-1 antibodies (%)</td>
<td>37.5</td>
<td>32.1</td>
<td>0.030</td>
<td></td>
</tr>
<tr>
<td>Positive anti-centromere antibodies (%)</td>
<td>25.7</td>
<td>34.5</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Elevated creatine–phosphokinase (%)</td>
<td>11.4</td>
<td>8.0</td>
<td>0.019</td>
<td></td>
</tr>
<tr>
<td>Elevation of acute phase reactants (%)</td>
<td>50.0</td>
<td>29.4</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Proteinuria (%)</td>
<td>15.3</td>
<td>5.45</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Active disease according to European score (%)</td>
<td>51.1</td>
<td>29.1</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>
Table 2 shows the ORs and 95% CI of associated factors with LV dysfunction.

**Table 2: Factors significantly associated with a reduced left ventricular ejection fraction**

<table>
<thead>
<tr>
<th></th>
<th>Univariate analysis</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Univariate analysis</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR 95% CI</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
<td>OR 95% CI</td>
<td></td>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>1.02 1.04-10.2</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>1.03 1.02-1.04</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Male gender</td>
<td>2.0 1.6-2.6</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>1.98 1.46-2.68</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>1.04 1.02-1.05</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>1.03 1.02-1.04</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Diffuse cutaneous subtype</td>
<td>1.92 1.56-2.36</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>1.38 1.06-1.81</td>
<td></td>
<td>0.018</td>
<td></td>
</tr>
<tr>
<td>Presence of friction rubs</td>
<td>1.96 1.50-2.55</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presence of synovitis</td>
<td>1.57 1.23-2.01</td>
<td></td>
<td>&lt;0.003</td>
<td></td>
<td></td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presence of digital ulceration</td>
<td>2.51 2.03-3.01</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>2.05 1.59-2.64</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Presence of muscle weakness</td>
<td>2.62 2.13-3.24</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>1.86 1.44-2.39</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Pulmonary fibrosis</td>
<td>2.39 1.94-2.95</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>1.33 1.02-1.72</td>
<td></td>
<td>0.034</td>
<td></td>
</tr>
<tr>
<td>Renal crisis</td>
<td>4.70 3.12-7.01</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>3.60 2.14-6.07</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Positive anti-topoisomerase-1 antibodies</td>
<td>1.27 1.02-1.58</td>
<td></td>
<td>0.030</td>
<td></td>
<td></td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive anti-centromere antibodies</td>
<td>0.66 0.52-0.83</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elevation of acute phase reactants</td>
<td>2.40 1.95-2.97</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active disease (European score)</td>
<td>2.55 2.06-316</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>1.42 1.09-1.86</td>
<td></td>
<td>0.011</td>
<td></td>
</tr>
<tr>
<td>Elevated systolic pulmonary artery pressure</td>
<td>2.63 2.03-3.41</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

It is noteworthy that men presenting with diffuse cutaneous SSc and active or past digital ulcerations, representing 203 patients (2.8%) in this study, were at particularly high risk of LV dysfunction (OR 3.2; 95% CI 2.1-4.9).

**Case-control analysis**
The second phase of the study included 385 patients including 129 with LVEF <55% and 256 controls. Diffuse cutaneous SSc was present in 145 patients, pulmonary fibrosis in 176, past or active digital ulcer in 204, and histories of renal crisis in 6 patients. Echocardiography revealed the presence of a systolic PAP >40 mmHg in 114 patients, of whom 34 had pre-capillary PAH confirmed by cardiac catheterization. Associated factors with reduced LVEF according to univariate and multivariate analyses are represented in table 3.
Table 3: Characteristics of SSc patients with and without abnormal left ventricular ejection fraction included in the nested case-control study.

<table>
<thead>
<tr>
<th></th>
<th>Left ventricular ejection fraction</th>
<th>Multivariate analysis (stepwise regression)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reduced (n=129)</td>
<td>Normal (n=256)</td>
</tr>
<tr>
<td>Age, y</td>
<td>59.8±12.7</td>
<td>56.2±12.8</td>
</tr>
<tr>
<td>Men/women (%)</td>
<td>33 / 67</td>
<td>12 / 88</td>
</tr>
<tr>
<td>Disease duration, mo</td>
<td>68.9±129.7</td>
<td>51.3±68.8</td>
</tr>
<tr>
<td>Diffuse/limited cutaneous</td>
<td>45/55</td>
<td>34 / 66</td>
</tr>
<tr>
<td>Smoking (past or present)</td>
<td>21.1</td>
<td>11.1</td>
</tr>
<tr>
<td>Systemic hypertension (%)</td>
<td>34.9</td>
<td>27.7</td>
</tr>
<tr>
<td>Body mass index</td>
<td>23.6±4.6</td>
<td>24.7±4.4</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>5.5</td>
<td>4.3</td>
</tr>
<tr>
<td>Presence of digital ulceration (%)</td>
<td>61.7</td>
<td>50</td>
</tr>
<tr>
<td>Presence of pulmonary fibrosis (%)</td>
<td>59.3</td>
<td>45.7</td>
</tr>
<tr>
<td>Forced vital capacity</td>
<td>84.5±23.6</td>
<td>94.1±21.1</td>
</tr>
<tr>
<td>Lung carbon monoxide diffusion; DLCO/VA</td>
<td>66.6±22.2</td>
<td>77.4±20.2</td>
</tr>
<tr>
<td>Echo sPAP</td>
<td>38.2±17.9</td>
<td>30.2±11.7</td>
</tr>
<tr>
<td>Pre-capillary PAH (%)</td>
<td>14.7</td>
<td>7.6</td>
</tr>
<tr>
<td>Myositis (%)</td>
<td>12.7</td>
<td>5.4</td>
</tr>
<tr>
<td>Renal crisis (%)</td>
<td>5</td>
<td>2.5</td>
</tr>
<tr>
<td>Positive anti-topoisomerase-1 antibodies (%)</td>
<td>31.2</td>
<td>37.8</td>
</tr>
<tr>
<td>Positive anti-centromere antibodies (%)</td>
<td>30.2</td>
<td>31.4</td>
</tr>
<tr>
<td>Use of CCB, past or present (%)</td>
<td>51.9</td>
<td>68.7</td>
</tr>
<tr>
<td>CCB for &gt;12 months (%)</td>
<td>45.7</td>
<td>60.2</td>
</tr>
<tr>
<td>Use of low dose prednisone (≤10 mg/d)</td>
<td>43.7</td>
<td>34.9</td>
</tr>
<tr>
<td>Use of immunosuppressors (%)</td>
<td>48.1</td>
<td>42.6</td>
</tr>
<tr>
<td>Use of endothelin antagonists (%)</td>
<td>16.3</td>
<td>9.8</td>
</tr>
</tbody>
</table>
We conducted similar analyses for LVEF <45% (n=36) that confirmed the above results (supplemental file 1).

Discussion
The main observations made in this analysis were i) a 5.4% prevalence of LV dysfunction, ii) the identification of age, male gender, myositis, digital ulcers, lung involvement and absence of previous CCB treatment as associated factors with reduced LVEF.

Large studies that evaluate LV dysfunction are sparse. In a multicenter study of PAH, a post hoc analysis identified only 8 of 570 SSc patients (1.4%) with LVEF <45% (2). The EUSTAR database offers a unique opportunity to study the complications of SSc. The 5.4% prevalence of reduced LVEF measured in the first phase of our study is concordant with the 7.2% prevalence among patients with diffuse SSc, and 5% in patients with limited SSc, observed in the first report from EUSTAR (8). Therefore, a depressed LVEF stands among the 4 main manifestations of major organ involvement in SSc, together with PAH (9-11), renal crisis (12) and interstitial lung disease.

The second objective was the identification of factors associated with a reduced LVEF. We used a two-step strategy that included 1) an analysis of the entire EUSTAR database, allowing the inclusion of robust factors unequivocally pertinent considering the large number of patients included, and 2) a nested prospective case-control study of a subgroup, that includes more data, such as atherosclerosis risk factors, drug regimen and the presence of pre-capillary PAH. In order to limit the impact of disease duration, a typical contributor to organ dysfunction, we matched our two study groups for disease duration. Both analyses confirmed that male gender, age, muscle involvement, digital ulceration were independent associated factors with LV dysfunction. The association between digital ulcerations and cardiac dysfunction may be a manifestation of the diffuse microvascular lesions, which characterize the disease (1). The significant association between systolic PAP and reduced LVEF observed in the first part of the study should be interpreted with caution, since systolic PAP is influenced by LV function, and this is emphasized by the lack of independent association with pre-capillary PAH found in the second part of our study. In the nested study, except for male gender, typical cardiovascular risk factors were not associated with a reduced LVEF, an observation concordant with the prior demonstration of a predominant contribution of microangiopathy, versus the controversial results regarding that of atherosclerosis, in the development of primary myocardial involvement in SSc (1). Another important finding of the nested study was the markedly lower proportion of patients with reduced LVEF who had been previously treated with CCB. This is concordant with previous short-term studies (1). In addition, Steen et al. reported that patients presenting with PAH were significantly less often treated with CCB than patients without PAH (13) and, in another study, the development of digital ulcers was also delayed by vasodilator therapy (14). Altogether, these observations suggest that CCB may protect against microvascular complications. Pending the results of long-term prospective study, the broad use of CCB in patients with SSc, unless contraindicated, should be strongly considered. Our study is limited by its observational design and since we studied patients with a LVEF <55%, which has not been associated with an increased mortality in patients with SSc, our results do not apply to mortality. We expect the prospective follow-up that is ongoing to enable the identification of predictors of LV dysfunction and outcome in SSc patients with mildly decreased LVEF.
Acknowledgement
EUSTAR is supported by research grant from EULAR and is under the auspices of the Standing Committee for International Studies Including Clinical Trials (ESCCA).

References:

METHODS

EUSTAR Registry

The European League Against Rheumatism (EULAR) Scleroderma Trials And Research (EUSTAR) MYOCARDIUM study is a two-phase program based on data collected in patients with SSc included in the EUSTAR registry. The structure and Minimal Essential Dataset (MEDS) of the EUSTAR database have been described previously in details (8). Briefly, since 2004, 150 participating medical centers entered consecutive patients in a registry, and all data in a specific database, which was locked for this study in April 2008. The registry includes demographic information, classification criteria, and a detailed clinical evaluation of SSc, that has been described elsewhere (8). Clinical variables include distinction of the cutaneous subset of the disease, disease duration, detection of antibodies and acute phase reactants, disease activity score, presence of active or past digital ulcerations, and the presence of renal, muscle, gastro-intestinal, pulmonary and cardiac involvement. Atherosclerotic risk factors and drug regimens were not recorded. LVEF was measured echocardiographically at each participating center, using Simpson’s method. LVEF was classified as depressed if <55% or <50%, depending on the cut-off value adopted at each echocardiography laboratory. Baseline data collected during the first patient visit at a EUSTAR center were analyzed.

Case-control study

In a second 18-month phase, EUSTAR centers identified in the first step as having included patients with reduced LVEF were asked to include a) SSc patients identified as having echocardiographic LVEF <55% in the first phase and consecutively reassessed in their respective center together with b) patients with SSc with normal LVEF (controls) who were enrolled in a 1:2 ratio in a nested case-control study, at the time of their next visit. Control patients 1) were entered in the registry either simultaneously or immediately after a patient with reduced LVEF, and 2) were matched for disease duration (±1 year). The data collected included te items of the EUSTAR registry, atherosclerosis risk factors, detailed pulmonary function tests, and drug regimen, including corticosteroids, calcium channel blockers (CCB) and endothelin antagonists prescribed for >3 months. Angiotensin converting enzyme inhibitors were only considered if prescribed before the occurrence of LV dysfunction. When pulmonary arterial hypertension (PAH) was suspected, catheterization was recommended to 1) confirm its presence, defined as a mean pulmonary arterial pressure (PAP) >25mmHg, and 2) identify patients with pre-capillary PAH. Myositis was defined by any clinical symptom (myalgia with or without weakness) together with an elevation in creatine phosphokinases values in the absence of any other potential explanation.

All patients included in either database granted their informed consent to participate, and the research program was approved by all appropriate institutional ethics committees.

STATISTICAL ANALYSES

Data were expressed as means ± standard deviation for continuous variables and numbers and percentages for categorical variables. From the EUSTAR registry, we first assessed the prevalence of LV dysfunction. To identify all potential factors associated with the existence of LV dysfunction, SSc patients with LV dysfunction were compared with SSc patients having normal LVEF using Student’s t-test for
comparisons of normally distributed continuous variables, and chi-square test for differences in frequency. Odds ratio (OR) estimates and 95% confidence intervals from logistic regression were then calculated. Due to multiple tests, p-values between 0.01 and 0.05 should be interpreted with caution. In order to identify independent factors associated with LV dysfunction, all variables with p<0.10 univariately, were entered as covariates in stepwise regression analysis. A similar protocol was used to identify associated factors with reduced LVEF in the second phase of the study (nested case-control). All analyses were performed with the STATA® statistical software, version 9.2 (StataCorp LP, College Station, TX). A p value <0.05 was considered statistically significant.

RESULTS
Although not planned by the original study protocol, we conducted multivariate analyses for associated factors with LVEF <45% (n=36) (4). Male gender (OR 2.62; 95% CI 1.17-5.89), diffuse SSc (OR 2.50; 95% CI 1.14-5.50) and absence of treatment with a CCB (OR 0.41; 95% CI 0.19-0.89) were associated by multiple variable analysis, and a trend was observed for digital ulcers (OR 2.06; 95% CI 0.89-4.79, p=0.09).
EUSTAR Coauthors:

(10) Pavillon Horloge 2° Hopital Saint Antoine 184 Faubourg Saint Antoine 75571 Paris cedex 12, France

(11) Research Laboratory and Division of Rheumatology Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, Italy

(12) Center for Autoimmune Diseases, Department of Medicine B, Sakler Faculty of Medicine, Tel-Aviv University, Israel

(13) Dipartimento Medicina Clinica e Sperimentale “F. Magrassi”, II Policlinico U.O. Reumatologia, Via Pansini, 5, I-80131 Napoli, Italy

(14) Institute of Rheumatic Diseases, Piestany, Národný ústav Reumatických Chorôb, Nábrežie I. Krasku 4782/4, 921 12 PIEŠŤANY, Slovak Republic

(15) Department of Rheumatology-Charité University Hospital, Schumannstr. 20/21, D-10117 Berlin, Germany

(16) Clinica Reumatologie – University of Medicine & Pharmacy “iuliu Hatieganu” Cluj, Str. Clinicilor nr. 2-4, 400006 Cluj-Napoca, România

(17) Université Paris Descartes, Groupe Hospitalier Cochin Saint-Vincent-De-Paul La Roche-Guyon, Rhumarologie A, 27, rue du Fg Saint-Jacques, 75679 Paris Cedex 14, France

(18) Department of Pathophysiology Medical School, National University of Athens 75 M. Asias str, Goudi, 11527 Athens, Greece

(19) Unità Operativa e Cattedra di Reumatologia (Dir. Prof. C. Montecucco), IRCCS Policlinico S. Matteo, 27100 Pavia, Italy

(20) Department of Dermatology the 1st Faculty of Medicine, Charles University, Prague, U nemocnice 2, 128 00 Praha 2, Czech Rep

(21) Istanbul Medical Faculty, Department of Internal Medicine, Division of Rheumatology 34390, Capa, Istanbul, Turkey

(22) Department of Rheumatology and Rehabilitation, Karol Marcinkowski University of Medical Sciences in Poznan, 61-545 Poznan, Ul. 28 Czerwca 1956 r. 135/147, Poland

(23) Hospital Universitario, 12 de Octubre, Servicio de Reumatología, Avda. De Córdoba, s/n 28041 Madrid, Spain

(24) Dep. of rheumatology and Clinical Immunology, Internal medicine, KBC Rijeka, Croatia

(25) Department of Immunology and Rheumatology, Faculty of Medicine, University of Pécs, H-7632 Pécs, Akác u.1., Hungary

(26) Department of Rheumatology, Hospital Santa Maria, Av Prof. Egas Moniz 1600 Lisbon (R. Virgilio Correia, 51 5° Drto 1600-222 Lisbon), Portugal

(27) Rheumatologische Ambulanz, Medizinische Klinik I, Universitätskliniken des Saarlandes, D-66421 Homburg/Saar, Germany

(28) Immunology and Allergy, University Hospital, 1211 Geneva 14, Switzerland

(29) Department of Internal Medicine and Rheumatology, Medical University of Silesia, ul. Ziołowa 45/47, PL 40-634 Katowice, Poland

(30) Dept. Rheumatology, Heinrich-Heine University, Düsseldorf Moorenstr. 5
40225 Düsseldorf, Germany
(31) Division of Rheumatology, Department of Medical and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy

(32) University Medical Center Ljubljana, Division of Internal Medicine, Department of Rheumatology, Vodnikova 62, 1000 Ljubljana, Slovenia

(33) “Stella Maris” 7 Kannizzata Street, Balzan, BZN 07-MALTA, Italy

(34) Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica Polo Didattico Universitá Politecnica delle Marche, Via Tronto, 10, 60020 Ancona, Italy

(35) Department of Internal Medicine Hopital Saint Louis, 1 avenue Claude Vellefaux, 75 010 PARIS, France

(36) Department of Rheumatology, Internal Medicin III, University of Vienna

AKH, Währinger Gürtel 18-20, A-1090 Wien, Austria

(37) Westpfalz-KliniKum Dep. Rheumatology Im Flur 1, D-66869 Kusel, Germany

(38) Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Leipzig, Stephanstraße 11, D-04103 Leipzig, Germany

(39) Department of Rheumatology Lund University Hospital, S-22185 Lund, Sweden

(40) Rheumatology Department of Internal Clinic. Clinical Hospital of Split Spinčiceva 1, 21000 Split, Croatia

(41) Dept. Of Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Arcispedale S. Anna, Corso Giovecca 203, 44100 Ferrara, Italy

(42) Universitätsklinik Köln, Joseph.Stelzmann Str. 9, D-50924 Köln, Germany

(43) Department of Dermatology, 02-008 Warsaw, Ul. Koszykowa 82-a, Poland

(44) Department of Dermatology, Georg-August-University Göttingen, Von-Siebold-Str. 3, D-37075 Göttingen, Germany

(45) Dept of internal Medicine, Rheumatology Unit, University of Pisa, Santa Chiara, Via Roma 67, 56126 Pisa, Italy

(46) General Hospital “Ag. Pavlos”, Department of Rheumatology, Eth. Antistaseos 161, 55134 Thessaloniki, Greece

(47) Ospedale Mauriziano, Centro di Reumatologia, Largo Turati 62, 10128 Torino, Italy

(48) Università degli Studi di Verona, Dipartimento di Medicina Clinica e Sperimentale, Reumatologia-Medicina Interna B, Policlinico GB Rossi

Piazzale LA Scuro 10, 37134 Verona, Italy

(49) Division of Clinical Immunology and Rheumatology, Dep. Of Internal, Medicine Dubrava University Hospital, Av. G. Šuška, 5, 10000 Zagreb, Croatia

(50) Centre for Rheumatology, Royal Free and University College London Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, United Kingdom

(51) Klinik für Dermatologie und, Allergologie, Universität Ulm, Maienweg 12, D-89081 Ulm, Germany
(52) Universitair Medisch Centrum St Radboud, Secretariat reumatologie, Huispost 546, PB 9101, 6500 HB Nijmegen, The Netherlands

(53) INSTITUTE OF RHEUMATOLOGY – BELGRADE, Resavska 69., 11000 BELGRADE, Serbia and Montenegro

(54) Universitätsklinikum Tübingen, Medizinische Klinik und Poliklinik, Internal Medicine/Rheumatology/ Haematology/Oncology, Otfried-Müller-Straße 10, D-72076 Tübingen, Germany

(55) Rheumatology Granollers General Hospital, Avgda Francesc Ribas,s/n, 8400 Granollers (Barcelona), Spain

(56) Department of Rheumatology Marienhospital Stuttgart, Böheimstraße 37
D-70199 Stuttgart, Germany

(57) Department of Dermatology Medical University of Lublin, 20-080 Lublin, Radziwillowska Str 13, Poland

(58) Medizinische Universitäts-Poliklinik, Dep. Of Rheumatology, Wilhelmstr. 35-37, D-53111 Bonn, Bonn, Germany

(59) Kantonsspital Aarau, Rheumaklinik und Institut für Physikalische Medizin und Rehabilitation, Kantonsspital Aarau, Tellstrasse, 5001 Aarau, Switzerland

(60) Leiden University Medical Center, Dept. of Rheumatology, Albinusdreef 2
2333 ZA Leiden, The Netherlands

(61) Klinikum der Johan Wolfgang Goethe – Universität, Medizinische Klinik III, Rheumatologische Ambulanz, Theodor-Stern-Kai 7 60590 Frankfurt am Main, Germany

(62) Kinder- und Jugendarthritisschule, Hamburger Zentrum für Kinder- und Jugendrheumatologie, Am Klinikum Eilbek, Dehnhaide 120, 22081 Hamburg, Germany

(63) Hospital son llàtzer, cta./ Manacor Km 4, 07198. Palma de Mallorca, Spain

(64) Arcispedale Santa Maria Nuova, Dipartimento Area Medica 1, UO di Reumatologia,Pad Spallanzani, Viale Umberto I°, 50, 42100 Reggio Emilia, Italy

(65) Department of Rheumatology Central Clinical Hospital MSW I A, Woloska 137 Warsaw, Poland

(66) Reumatologia, Hospitais da Universidade, 3000-075 Coimbra, Portugal

(67) Department of Rheumatology Rigshospitalet, University of Copenhagen
Blegdamsvej 9, 2100 Copenhagen, Denmark

(68) Charité – Universitätsmedizin Berlin, Department of Dermatology and Allergy, Schumannstr. 20/21, 10117 Berlin, Germany

(69) Medizinische Universität Graz, Medizinische Universitätsklinik - Abteilung für Rheumatologie, Auenbruggerplatz 15, 8052 Graz, Austria

(70) Dept. Of Dermatology, University of Düsseldorf, Moorstrasse 5, D-40225 Düsseldorf, Germany

(71) Institute for prevention, treatment and rehabilitation rheumatic and cardiovascular disease Niska Banja, Srpskih Junaka 2, 18205 Niska Banja, Serbia and Montenegro

(72) Rheumatology Unit - Humanitas Clinical Institute, Via Manzoni, 56
20089 - Rozzano (Milan), Italy
(73) Department of Reumatology and Connective Tissue Diseases, Medical University of Lublin, 20-090 Lublin, Jaczewskiego 8, Poland

(74) Clinical Center Skopje, Rheumatology Clinic "Dr Dimitar Arsov", University "St. Cyril and Methodius", Vodnjanska 17, 1000 Skopje, FYR Macedonia

(75) Rheumatology Unit, Department of Medicine, Chris Hani Baragwanath Hospital and University of the Witwatersrand, P.O. Bertsham 2013 Johannesburg, South Africa

(76) Institute of Rheumatology, Russian Academy of Medical Science, Kashirskoye shosse,34 A, 115522 Moscow, Russian

(77) Department of Dermatology, University of Mainz, Langenbeckstr. 1, D-55131 Mainz, Germany

(78) Hope Hospital/University of Manchester, Rheumatic Diseases Centre, Clinical Sciences Building, Stott Lane, Salford M6 8HD, United Kingdom

(79) Kerckhoff-Klinik Bad Nauheim, Benekestr. 2-8, D-61231 Bad Nauheim, Germany

(80) Gulhane Military Medical Academy Division of Rheumatology, GATA Romatoloji Bilim Dali, 06018- Etilk, Ankara, Turkey

(81) UO Immunologia Clinica- Centro di Riferimento per le Malattie Autoimmuni Sistemiche, Via Pace 9 -20122 Milano, Italy

(82) Aarhus University Hospital, Department of Rheumatology, Noerrebrogade 44, 8000 Aarhus, Denmark

(83) Clinica di medicina interna ad orientamento immunologico Università di Genova, c/o Azienda Ospedale- Università San Martino, Viale Benedetto XV, 6 16132 Genova, Italy

(84) Dept of Rheumatology and Endocrinology, Herlev, Denmark

(85) Third Department of Medicine, Rheumatology Division, University of Debrecen, Medical Center, Hungary

(86) Division of Rheumatology & Immunology, 96 Jonathan Lucas Street, Suite 912, P.O. Box 250637, Charleston, South Carolina, USA

(87) Ospedale L. Sacco - Azienda Ospedaliera-Polo Universitario, Unità Operativa di Reumatologia, Via G.B. Grassi 74, 20157 Milano, Italy

(88) Consulta Reumatologia Hospital deMendaro, B°Mendarozabal s/n. 20850 Mendaro Guipuzcoa, Spain

(89) Servicio de Reumatologia, Hospital Ramon Y Cajal, Carretera de Colmenar, km.9,100, 28034 Madrid, Spain

(90) Dep. of Rheumatology, Rikshospitalet, Oslo, Norway, Rikshospitalet Oslo, Norway

(91) Department of Internal Medicine, Hôpital Claude Huriez, Place de Verdun 59035 Lille cedex, France

(92) Divisione Di Reumatologia - Universita' Di Roma La Sapienza Dipartimento Di Clinica e terapia medica applicata, policlinico Umberto I, Viale Del Policlinico 155, 00161 Roma, Italy

(93) North-Estonian Regional Hospital, Estonia

(94) "Carol Davila" University of Medicine &Pharmacy, Department of Internal Medicine and Rheumatology Spitalul "Sf.Maria" Bucharest, 37-39, Ion Mihalache Blvd, Bucharest, Romania
(95) Day Hospital Rheumatology, “Gaetano Pini”, Via Pini 3, 20122 Milano, Italy

(96) Hospital São João, Serviço de Reumatologia, Alameda Hernani Monteiro, 4202-451 Porto, Portugal

(97) Johns Hopkins University, Division of Rheumatology, Johns Hopkins School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA

(98) Clinic of Internal Medicine and Rheumatology, Dr I Cantacuzino Hospital and Early Arthritis Center, Ion Movila 5-7 street, sector 2, Bucharest, Romania

(99) Prof. Dr. D. Gerota* Emergency Hospital; Dep. of Rheumatology, Bd. Ferdinand No 50, sector 2, Bucharest, Romania

(100) Department of Dermatology, University of Münster, Von-Esmarch-Str. 58 48149 Münster, Germany

(101) Sect of Scleroderma & Myositis, Dept of Rheumatol, The Hosp for Rheum Dise, Hanyang Univ 17 Haengdang-Dong, Sungdong-Gu, Seoul 133-792, Korea

(102) Thomas Jefferson University, 613 Curtis Building, 1015 Walnut Street, Philadelphia, PA 19107, USA

(103) Rheumatology and Rehabilitation Department, Ibninsina Teaching Hospital, Al-Shifaa Mosul, Iraq

(104) Department of Internal Medicine 3, Universitätsstr. 29, 91054 Erlangen , Germany

(105) University Medical Centre Utrecht, Heidelbergaal 100, F02.207, 3584CX Utrecht, The Netherlands

(106) 2nd Dpt of Internal Medicine Faculty Hospital and Medical Faculty in Hradec Kralove, UK Praha, Sokolska street 581,Hradec Kralove 500 05, Czech Republic

(107) University of Michigan Scleroderma Program, 3918 Taubman Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0358, USA

(108) Dipartimento e Cattedra di Reumatologia, Università degli Studi di Milano, Istituto Ortopedico Gaetano Pini, Piazza Cardinal Ferrari, 1, 20122 Milano, Italy

(109) Rheumatology Research Unit, Post Office Box 368, Maroochy waters, Sunshine coast 4558 Queensland, Australia

(110) Department of Internal Medicine, Hôpital Cochin, 27 rue du Faubourg Saint jacques, 75014 Paris, France

(111) University of Ghent, Department of rheumatology, de pintelaan 185, 9000 Ghent, Belgium

(112) Celal Bayar University Medical School, PM&R department, Manisa, Turkey

(113) U.O. Reumatologia - Università degli Studi di Foggia, Ospedale "Col. D'Avanzo", Viale degli Aviatori – 71100 Foggia, Italy

(114) Dep. Dermatology, HS-Bispebjerg hospital university hospital of Copenhagen, Department of Dermatology D-40, HS-Bispebjerg Hospital University Hospital of Copenhagen, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark

(115) Rheuma Clinic, Av. Carlos Gomes 328/1009, Porto Alegre, RS, 90480-000, Brasil

(116) Dipartimento di Medicina, DH Reumatologia e Malattie Autoimmuni – Ospedale san Gerardo, Via Pergolesi 33, 20052 Monza (Mi), Italy
(117) Department of dermatology and allergy of the TU Munich, Biedersteiner Straße 29, 80802 Munich, Germany

(118) Department of Rheumatology and Internal Diseases, Wrocław University of Medicine Ul. Borowska 213, 50-556 Wrocław, Poland

(119) Pontifical Catholic University – School of Medicine, Avenida Ipiranga 6690, Sala 220 – Reumatologia, Porto Alegre, RS, CEP-90610-00, Brasil

(120) Université catholique de Louvain, Cliniques Universitaires St-Luc, Avenue Hippocrate 10, B-1200 Bruxelles, Belgium

(121) Hospital Universitario Dr Peset, Avda. Gaspar Aguilar, 90. 46017-Valencia, Spain

(122) Endokrinologikum Frankfurt, Stresemannallee 3, 60596 Frankfurt, Germany

(123) Division of Rheumatology, Department of Medicine III, University Medical Center Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany

(124) Secretariat Reumatologije<BR>Herestraat 49<BR>3000 Leuven, Belgium

(125) Sezione Reumatologia - Dip.to Medicina Clinica e Scienze Immunologiche - Università di Siena, Policlinico le Scotte, Viale Bracci, 53100 Siena, Italy

(126) University Hospital Centre Zagreb, Division of clinical immunology and rheumatology Department of medicine, Kispaticeva 12, 10000 Zagreb, Croatia

(127) Klinikum Darmstadt, Med. Klinik III, Nephrology, Hypertension and Rheumatology<br>Grafenstr. 9, D-64283 Darmstadt, Germany

(128) East-Tallinn Central Hospital, Departement of Rheumatology, Pärnu mnt 104, 11312 Tallinn, Estonia

(129) Unità di Reumatologia, Dipartimento di Medicina Generale, Ospedale Sacro Cuore - Don Calabria, Negraz 37024 (VR) - Via Don Sempreboni, 5, Italy

(130) Reha Rheinfelden, DIV, Salinenstrasse 98, CH-4310 Rheinfelden, Switzerland

(131) University of Marmara, Dept of Rheumatology, Topkhamioglu cad.No:81, Altunize-Istanbul, 34700, Turkey

(132) Service de Médecine Interne, Hôpital Nord, Chemin des Bourrely, 13915 Marseille, France

(133) Universidade Federal do Paraná, Rua Padre Camargo, 241, 80060-240, Curitiba-Paraná, Brasil

(134) Scleroderma Center - Thomas Jefferson University, 233 s 10th street, BLSB 509 19107 Philadelphia, USA

(135) Department of Rheumatology, Republican Clinicla Hospital, 29, N. Testemitanu str, Chisinau, MD2025, Republic of Moldova

(136) Department of medicine, Unit of internal medicine, 179 boulevard marechal Juin<br>26953 VALENCE cedex 9, France

(137) Hospital de Clínicas de Porto Alegre, Ramiro Barcelos, 2350-s.645, Porto Alegre/RS ZIP: 90035-903, Brasil

(138) Kaunas University of Medicine Hospital, Department of Rheumatology, Eiveniu str. 2, Kaunas LT-3007, Lithuania

(139) Dunedin School of Medicine, P O Box 9i3, Dunedin, 9054 , New Zealand
(140) II Chair of Rheumatology, University of Cagliari, Head Prof. Alessandro Mathieu, Policlinico Universitario, S.S. 554, bivio per Sestu, 09042 Monserrato (CA), Italy

(141) Clinica Dermatologica Università di Chieti, Italy

(142) Complexo Hospitalar Santa Casa de Porto Alegre, Hospital Santa Clara, Rua Prof. Annes Dias, 135, Brasil

(143) University of São Paulo - Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo. Av. Dr. Arnaldo, 455 - 3 Reumatologia, sala 3107 São Paulo, SP, 01246-000, Brasil

(144) Faculdade de Medicina de São José do Rio Preto-SP, Av. Brigadeiro Faria Lima, 5416, São Pedro, São José do Rio Preto - São Paulo, Brasil

(145) Christchurch New Zealand, Dept of Medicine, University of Otago, Christchurch, P.O. Box 4345, Christchurch, New Zealand
Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients

Y Allanore, C Meune, M C Vonk, et al.

Ann Rheum Dis published online March 10, 2009
doi: 10.1136/ard.2008.103382

Updated information and services can be found at:
http://ard.bmj.com/content/early/2009/03/10/ard.2008.103382

These include:

Data Supplement
“Web Only Data”
http://ard.bmj.com/content/suppl/2010/01/29/ard.2008.103382.DC1.html

References
Article cited in:
http://ard.bmj.com/content/early/2009/03/10/ard.2008.103382#related-urls

Published online March 10, 2009 in advance of the print journal.

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/